ABELTINO, Manuela
 Distribuzione geografica
Continente #
EU - Europa 667
NA - Nord America 561
AS - Asia 356
AF - Africa 20
Continente sconosciuto - Info sul continente non disponibili 1
Totale 1.605
Nazione #
US - Stati Uniti d'America 545
CN - Cina 233
IT - Italia 177
SE - Svezia 165
FI - Finlandia 101
IE - Irlanda 99
TR - Turchia 49
DE - Germania 43
SG - Singapore 39
UA - Ucraina 22
CI - Costa d'Avorio 19
JP - Giappone 18
CA - Canada 16
RO - Romania 16
BE - Belgio 14
AT - Austria 10
VN - Vietnam 8
IN - India 7
CZ - Repubblica Ceca 6
GB - Regno Unito 4
BG - Bulgaria 2
CH - Svizzera 2
DK - Danimarca 2
ES - Italia 2
NL - Olanda 2
CM - Camerun 1
EU - Europa 1
IR - Iran 1
PK - Pakistan 1
Totale 1.605
Città #
Dublin 99
Chandler 91
Ann Arbor 85
Jacksonville 54
Parma 50
Izmir 41
Nanjing 40
Ashburn 38
Beijing 36
Dearborn 31
Boardman 28
Singapore 24
San Mateo 21
Shanghai 20
Abidjan 19
Tokyo 18
Bologna 16
Focsani 16
Princeton 16
Toronto 16
Nanchang 15
Shenyang 15
Brussels 14
Falls Church 14
Kunming 14
Jinan 13
Des Moines 10
Wilmington 10
Vienna 9
Bremen 8
Dong Ket 8
Hebei 8
Jiaxing 8
Kocaeli 8
New York 8
Düsseldorf 7
Hangzhou 7
Milan 7
Arzano 6
Changsha 6
Hefei 6
Helsinki 6
Piacenza 6
Redmond 6
Cambridge 5
Santa Clara 5
Taizhou 5
Verona 5
Langhirano 4
Novara 4
Reggio Emilia 4
Savignano Sul Rubicone 4
Seattle 4
Tianjin 4
Woodbridge 4
Brno 3
Chengdu 3
Los Angeles 3
Modena 3
Mountain View 3
Reggio Nell'emilia 3
Zhengzhou 3
Amsterdam 2
Cremona 2
Frederiksberg 2
Fremont 2
Fuzhou 2
Gurgaon 2
Guwahati 2
Inzago 2
Leawood 2
Madrid 2
Marghera 2
Mestre 2
Olomouc 2
Orange 2
Padova 2
Pune 2
Redwood City 2
Rockville 2
Sala Baganza 2
Treviso 2
Walnut 2
Abbiategrasso 1
Ahmedabad 1
Ardabil 1
Bari 1
Bioggio 1
Böblingen 1
Chongqing 1
Clifton 1
Council Bluffs 1
Dallas 1
Fidenza 1
Guangzhou 1
Haikou 1
Jinhua 1
Monza 1
Nanning 1
Ningbo 1
Totale 1.106
Nome #
Functional interplay between NIK and c-Abl kinases limits response to Aurora inhibitors in multiple myeloma 201
MEK-INHIBITORS/ARSENIC TRIOXIDE COMBINATION THERAPY AS A NOVEL TREATMENT OPTION FOR TYROSINE KINASE INHIBITORS-RESISTANT PH+-LEUKEMIA 124
The Pharmacological Blockade of Phosphodiesterase IV Potentiates the Anti-Tumor Effects of Arsenic Trioxide (ATO) in Acute Myelogenous Leukemia Cells through Multiple Signaling Pathways 123
Are the Myeloma bone microevironment cells tumoral or not? 102
HOXB7 expression by myeloma cells regulates their pro-angiogenic properties in multiple myeloma patients 94
CC-4047 (Pomalidomide) inhibits multiple myeloma-induced osteoclast formation targeting RANKL in the bone marrow microenvironment 93
The homeobox gene HOXB7 regulates the production of pro-angiogenic molecole by myeloma cells and it is a target in myeloma-induced angiogenesis 88
The Immunomodulatory drugs Lenalidomide and Pomalidomide inhibit multiple myeloma-induced osteoclast formation and RANKL/OPG ratio in myeloma microenvironment targeting the expression of adhesion molecules 87
HOXB7 is a key gene involved in Myeloma cell growth and Myeloma-induced angiogenesis in Multiple Myeloma patients 87
The IMID CC-4047 (Pomalidomide) inhibits myeloma-induced osteoclast formation 85
HOXB7 is critically involved in Multiple Myeloma-induced angiogenic switch 76
Oxygen tension in the bone marrow (BM) of patients with malignant and indolent monoclonal gammopathy: role of hypoxia and hypoxia-inducible factor (HIF)-1{alpha} in the regulation of gene expression and pro-angiogenic profiles of CD138+ cells 75
Non canonical wnt signal pathway (Wnt5a/ror2) activation stimulates the osteogenic differentiation process of bone mesenchymal cells being a potential target in multiple myeloma bone disease 72
Myeloma cells inhibit the non-canonical wnt co-receptor ror2 in human mesenchymal/osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on mm-induced impairment of the osteogenic differentiation process 67
Increased osteocyte apoptosis in Multiple Myeloma patients: a potential role in bone remodeling alterations related to osteolytic bone lesions 67
In vitro and In vivo evidences of osteocytes involvement in myeloma-induced osteolysis 65
MEK1/2 regulate normal BCR and ABL1 tumor-suppressor functions to dictate ATO response in TKI-resistant Ph+ leukemia 53
MEK1/2 KINASES DISABLE THE TUMOR SUPPRESSOR FUNCTIONS OF NATIVE BCR AND ABL1 KINASES TO IMPAIR ANTICANCER DRUGS’ RESPONSIVENESS IN TKI-RESISTANT PHILADELPHIA POSITIVE LEUKEMIAS 53
MEK-INHIBITORS/ARSENIC TRIOXIDE COMBINATION THERAPY AS A NOVEL TREATMENT OPTION FOR TYROSINE KINASE INHIBITORS-RESISTANT PH plus -LEUKEMIA 32
Totale 1.644
Categoria #
all - tutte 5.688
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.688


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020219 0 0 18 3 19 33 37 12 23 36 16 22
2020/2021197 1 16 5 1 47 16 3 8 48 15 21 16
2021/2022179 5 8 4 31 9 10 20 18 9 11 25 29
2022/2023402 56 53 35 26 46 29 14 9 110 5 15 4
2023/2024220 17 13 13 7 24 38 19 9 7 15 10 48
2024/2025106 51 31 24 0 0 0 0 0 0 0 0 0
Totale 1.644